Announcements Trials
Browse Landscape

Phase

Phase 2 23Phase 3 5Phase 1/2 5Phase 2/3 3Phase 1 1

Status

Not yet recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 15Stomach Neoplasms 11Colonic Neoplasms 7Carcinoma, Hepatocellular 7Rectal Neoplasms 4Pancreatic Neoplasms 3Neoplasms 3Biliary Tract Neoplasms 3Lymphoma, Large B-Cell, Diffuse 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Adenocarcinoma 2Vipoma 1Somatostatinoma 1Resected Liver Metastases From Colorectal Cancer 1Recurrence 1Quality of Life 1Pathologic Complete Response 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Liver Neoplasms 1Insulinoma 1Immunotherapy Gastrict Cancer 1HER2-positive Gastric Cancer 1Glucagonoma 1Gastroesophageal Junction Adenocarcinoma 1Gastrinoma 1Esophageal Squamous Cell Carcinoma 1

Interventions

Gemcitabine 4Cisplatin 4Capecitabine 4Oxaliplatin 3Leucovorin 2Fluorouracil 2Albumin-Bound Paclitaxel 2titanium silicide 1tegafur-gimeracil-oteracil 1surufatinib 1pembrolizumab 1mitazalimab 1durvalumab 1cediranib 1anlotinib 1Taxes 1S 1 (combination) 1Paclitaxel 1Folfox protocol 1Control Groups 1ARRY-334543 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Biliary Tract Neoplasms × Oxaliplatin × Clear all
NCT07437287 2026-02-27

CROCOBIL

UNICANCER

Phase 2/3 Not yet recruiting
160 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT06214572 2025-04-11

RUGB

Tata Memorial Centre

Phase 2/3 Recruiting
249 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms

NCT06662877 2024-10-29

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

Sun Yat-sen University

Phase 2/3 Not yet recruiting
206 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡